[Contribution of bone quality to fracture risk].
Recently Bone quality has been recognized as an important contributing factor of bone strength, as clearly stated in NIH (National Institute of Health) consensus development panel of 2000 that bone strength reflects both bone density and bone quality. Bone quality refers to architecture, turnover, damage accumulation, mineralization and matrix. In the treatment of osteoporosis anti-resorptive agents increase bone strength with decreasing bone turnover. It is important to control bone turnover within favorable range to increase bone strength without deterioration of bone quality.
Mori
Satoshi
S
Department of Orthopedic Surgery, Faculty of Medicine, Kagawa University.
D015519:Bone Density; D001857:Bone Matrix / Q000378:metabolism; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D002113:Calcification, Physiologic; D018849:Controlled Clinical Trials as Topic; D005260:Female; D005265:Femoral Neck Fractures / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*; D016103:Spinal Fractures / Q000209:etiology* / Q000517:prevention & control*
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride